SAN ANTONIO (EGMN) - More than half of breast cancer patients who experience joint symptoms on one nonsteroidal aromatase inhibitor don't experience them on the other, results of a randomized, prospective trial suggest.Moreover, at least three-quarters of patients who develop joint pain and/or stiffness on the nonsteroidal aromatase inhibitors (AIs) anastrozole (Arimidex) or letrozole (Femara) no longer experience joint symptoms if they are switched to tamoxifen, study investigator Dr. J. Michael...